Oncocross Co., Ltd. (KOSDAQ:382150)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Discovery and Development of Drugs	1.07B	91.52M	150.25M	100.00M	90.00M
Discovery and Development of Drugs Growth	1071.49%	-39.08%	50.25%	11.11%	-
Total	1.07B	91.52M	150.25M	100.00M	90.00M
Total Growth	1071.49%	-39.08%	50.25%	11.11%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
South Korea	1.07B	91.52M	150.25M	100.00M	90.00M
South Korea Growth	1071.49%	-39.08%	50.25%	11.11%	-
Total	1.07B	91.52M	150.25M	100.00M	90.00M
Total Growth	1071.49%	-39.08%	50.25%	11.11%	-

Source: S&P Global Market Intelligence.